In the landscape of modern drug discovery, the perception of change often lags behind the reality of scientific progress. To the casual observer, the rise of New Approach Methodologies (NAMs)—non-animal testing methods designed to predict human safety—might appear as a sudden, disruptive shift prompted by the 2022 signing of the FDA Modernization Act 2.0. However, for those in the trenches of pharmaceutical R&D, this transition is the culmination of more than ten years of rigorous scientific validation, strategic regulatory engagement, and a fundamental reassessment of how we define "human-relevant" data.
The cardiac safety sector, in particular, has emerged as the vanguard of this movement. By moving beyond legacy animal models, which have historically struggled to bridge the gap between preclinical findings and human clinical outcomes, the industry is successfully ushering in a new era of precision toxicology.
A Chronology of Change: From Tox21 to Regulatory Acceptance
The journey toward modern cardiac safety assessment did not begin with legislation; it began with the realization that traditional, animal-based assays were hitting a ceiling. Despite decades of refinement, late-stage drug attrition due to unforeseen cardiac toxicities remained a persistent and costly hurdle.
The Foundations (2010–2015)
The early 2010s marked a departure from the "black box" approach of traditional animal toxicology. Initiatives such as Tox21 and ToxCast laid the intellectual groundwork by advocating for mechanism-based assays. The scientific community began to coalesce around the idea that human-derived cells, coupled with sophisticated recording technologies, could offer a more predictive window into human biology than rodent models.
The CiPA Breakthrough (2015–2020)
The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative served as the turning point for credibility. By bringing together pharmaceutical giants, CROs, and global regulators, CiPA established a framework for assessing proarrhythmic risk using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). This was the first time the industry moved collectively toward a consensus that human-relevant physiology could be quantified and standardized.
Regulatory Integration (2020–Present)
The final stage of this evolution has been the formalization of these tools within regulatory workflows. The FDA’s Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program provided the missing link: a structured dialogue between developers and regulators. This program transformed NAMs from internal R&D curiosities into "fit-for-purpose" evidence that now supports Investigational New Drug (IND) applications.
The Technological Engine: MEA and iPSC-CMs
At the heart of this success is the convergence of two technologies: induced pluripotent stem cells (iPSCs) and microelectrode array (MEA) systems.
iPSCs allow scientists to generate human heart muscle cells that carry the genetic and functional traits of human tissue. When these cells are cultured on an MEA platform—such as the Maestro MEA—researchers can perform continuous, non-invasive monitoring of cardiac electrophysiology. Unlike traditional patch-clamp techniques, which are labor-intensive and provide only a "snapshot" of cellular activity, MEA technology offers longitudinal, real-time data on how a drug candidate interacts with human heart cells over time.
This platform has become the gold standard for detecting delayed repolarization and arrhythmia-like events—specifically the risk of torsades de pointes, a rare but lethal ventricular arrhythmia. The scalability of these systems has allowed them to permeate the entire pharmaceutical ecosystem, from early discovery to late-stage safety assessment.
Supporting Data: Evidence of Efficacy
The shift toward these methodologies is not driven by ideology, but by performance. Data released in a 2025 study by FDA scientists underscores the accelerating adoption of these tools. Between 2020 and 2023, the number of IND submissions incorporating hiPSC-CM MEA data doubled compared to the entire decade prior.
Key Performance Indicators
Recent, peer-reviewed research indicates that hiPSC-CM data provides higher predictive performance than the standard "trio" of legacy methods: hERG assays, multi-ion channel approaches, and traditional animal QT studies.
- Reduction in False Negatives: When used in combination with other in vitro assays, hiPSC-CM data significantly reduces the rate of nonclinical QT false negatives.
- Clinical Concordance: The data demonstrates a strong, consistent correlation with clinical QT outcomes in human trials, providing a bridge between the bench and the bedside that animal models simply cannot replicate.
- Voluntary Adoption: Perhaps the most compelling evidence of utility is that hiPSC-CM data is not currently a regulatory requirement. The fact that sponsors are voluntarily including these studies—and that 16 major CROs now offer CiPA-style hiPSC-CM assays as a standard service—proves that these models deliver real, tangible value in risk mitigation.
The Path Forward: Scaling Through Standards
As NAMs move from "novelty" to "standard practice," the industry faces a new hurdle: consistency. Without uniform benchmarks, variability in how these models are implemented could undermine the very confidence that took a decade to build.
To address this, the Axion iPSC Model Standards (AIMS) initiative was launched. This collaborative effort seeks to define what "good" looks like in a cardiac safety assay. By setting benchmarks for baseline electrophysiological performance, acceptable levels of variability, and expected cellular responses to reference compounds, the AIMS initiative provides a roadmap for responsible scaling.
This is the maturation of the NAM movement: moving from proving that these methods can work to proving that they work consistently across different laboratories, different cell lines, and different drug classes.
Implications for Safety Organizations
For safety leaders and toxicologists, the current environment presents a unique inflection point. The "sudden" legislative changes were merely a reflection of a field that had already matured behind the scenes.
Avoiding the "Legacy Trap"
The real risk in today’s drug development climate is not the adoption of new, unfamiliar methods; it is the continued reliance on antiquated models that fail to capture the nuances of human cardiac biology. Organizations that fail to transition to human-relevant, mechanism-based NAMs risk falling behind competitors who are using these tools to make faster, more informed, and more accurate safety decisions.
A Measured, Evolutionary Transition
The shift to NAMs is not a "disruptive" process that threatens to break existing workflows. Instead, it is an evolutionary one. Because platforms like the Maestro MEA were designed to be operational and practical, they integrate seamlessly into existing CRO and pharma pipelines.
The mandate for the next decade is clear:
- Embrace Regulatory Engagement: Utilize programs like ISTAND to align on expectations early.
- Prioritize Human-Relevant Data: Shift focus from animal-centric models to human-derived, functional assays.
- Champion Standardization: Participate in initiatives like AIMS to ensure that as the industry scales, the quality and reliability of the data remain ironclad.
Conclusion
The evolution of cardiac safety assessment serves as a template for the future of drug discovery. It demonstrates that the most successful transitions are those built on a foundation of years of collaborative science rather than top-down mandates. By replacing the guesswork of animal models with the precision of human-relevant, functional assays, the pharmaceutical industry is not only meeting regulatory expectations—it is proactively raising the bar for patient safety.
As we look toward the next chapter of drug development, the narrative of a "sudden shift" should be replaced by a more accurate understanding: this is the result of a decade of hard work, scientific integrity, and a collective commitment to creating safer, more effective medicines for the patients who need them most.
Mike Clements, PhD, is the SVP of Scientific Partnerships & Strategy at Axion BioSystems. His career has been dedicated to bridging the gap between innovative stem cell research and practical, regulatory-ready toxicology solutions. As an editor of "Stem Cell-Derived Models in Toxicology" and a former leader in the Society of Toxicology, Clements remains at the forefront of the effort to standardize and scale the next generation of drug safety testing.
About the Author
